{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:23:52Z","timestamp":1787786632461,"version":"build-2784847793"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00103-018-2835-7","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T10:23:54Z","timestamp":1541413434000},"page":"1528-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Geb\u00e4rmutterhalskrebsscreening in Deutschland","Cervical cancer screening in Germany"],"prefix":"10.1007","volume":"61","author":[{"given":"Janina","family":"Bujan Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie J.","family":"Klug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"2835_CR1","volume-title":"Cervical cancer","author":"World Health Organization","year":"2018","unstructured":"World Health Organization (2018) Cervical cancer. \n                    http:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/cervical-cancer\/en\/\n                    \n                  . Zugegriffen: 15. M\u00e4rz 2018"},{"key":"2835_CR2","volume-title":"Krebs in Deutschland 2013\/2014","author":"Robert Koch-Institut","year":"2017","unstructured":"Robert Koch-Institut (2017) Krebs in Deutschland 2013\/2014. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.\u202fV, Berlin"},{"key":"2835_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0042-6822(91)90816-T","volume":"184","author":"H Hausen zur","year":"1991","unstructured":"zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9\u201313","journal-title":"Virology"},{"key":"2835_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JMM Walboomers","year":"1999","unstructured":"Walboomers JMM, Jacobs MV, Manos MM et\u00a0al (1999) Human papillomavirus is a\u00a0necessary cause of invasive cervical cancer worldwide. J\u00a0Pathol 189:12\u201319","journal-title":"J Pathol"},{"key":"2835_CR5","first-page":"1","volume":"63","author":"LE Markowitz","year":"2014","unstructured":"Markowitz LE, Dunne EF, Saraiya M et\u00a0al (2014) Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63:1\u201330","journal-title":"MMWR Recomm. Rep."},{"key":"2835_CR6","volume-title":"Agents classified by the IARC monographs","author":"International Agency For Research On Cancer","year":"2018","unstructured":"International Agency For Research On Cancer (2018) Agents classified by the IARC monographs. \n                    https:\/\/monographs.iarc.fr\/ENG\/Classification\/ClassificationsGroupOrder.pdf\n                    \n                  . Zugegriffen: 20. Apr. 2018"},{"key":"2835_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890\u2013907","journal-title":"Lancet"},{"key":"2835_CR8","volume-title":"Human papillomavirus (HPV) and cervical cancer. Key facts","author":"World Health Organization","year":"2016","unstructured":"World Health Organization (2016) Human papillomavirus (HPV) and cervical cancer. Key facts. \n                    http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/human-papillomavirus-\n                    \n                  (hpv)-and-cervical-cancer. Zugegriffen: 6. M\u00e4rz 2018"},{"key":"2835_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","volume":"41","author":"HW Chesson","year":"2014","unstructured":"Chesson HW, Dunne EF, Hariri S, Markowitz LE (2014) The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41:660\u2013664","journal-title":"Sex Transm Dis"},{"key":"2835_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1023\/B:CACO.0000003811.98261.3e","volume":"14","author":"M Plummer","year":"2003","unstructured":"Plummer M, Herrero R, Franceschi S et al (2003) Smoking and cervical cancer: pooled analysis of the IARC multi-centric case\u2014control study. Cancer Causes Control 14:805\u2013814","journal-title":"Cancer Causes Control"},{"key":"2835_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","volume":"370","author":"P Appleby","year":"2007","unstructured":"Appleby P, Beral V, Berrington de Gonzalez A et\u00a0al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609\u20131621","journal-title":"Lancet"},{"key":"2835_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(02)08151-5","volume":"359","author":"N Munoz","year":"2002","unstructured":"Munoz N, Franceschi S, Bosetti C et al (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359:1093\u20131101","journal-title":"Lancet"},{"key":"2835_CR13","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hernandez-Ramirez","year":"2017","unstructured":"Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA (2017) Cancer risk in HIV-infected people in the USA from 1996 to 2012: a\u00a0population-based, registry-linkage study. Lancet HIV 4:e495\u2013e504","journal-title":"Lancet HIV"},{"key":"2835_CR14","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/sj.bjc.6601219","volume":"89","author":"J Adami","year":"2003","unstructured":"Adami J, Gabel H, Lindelof B et\u00a0al (2003) Cancer risk following organ transplantation: a\u00a0nationwide cohort study in Sweden. Br J Cancer 89:1221\u20131227","journal-title":"Br J Cancer"},{"key":"2835_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2334-13-140","volume":"13","author":"H Ali","year":"2013","unstructured":"Ali H, Guy RJ, Wand H et al (2013) Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 13:140","journal-title":"BMC Infect Dis"},{"key":"2835_CR16","first-page":"584","volume":"111","author":"Y Delere","year":"2014","unstructured":"Delere Y, Wichmann O, Klug SJ et al (2014) The efficacy and duration of vaccine protection against human papillomavirus: a\u00a0systematic review and meta-analysis. Dtsch Arztebl Int 111:584\u2013591","journal-title":"Dtsch Arztebl Int"},{"key":"2835_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1098-3","author":"T Harder","year":"2018","unstructured":"Harder T, Wichmann O, Klug SJ, van der Sande M, Wiese-Posselt M (2018) Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a\u00a0systematic review. BMC Med. \n                    https:\/\/doi.org\/10.1186\/s12916-018-1098-3","journal-title":"BMC Med"},{"key":"2835_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10552-015-0568-6","volume":"26","author":"JM Brotherton","year":"2015","unstructured":"Brotherton JM, Saville AM, May CL, Chappell G, Gertig DM (2015) Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control 26:953\u2013954","journal-title":"Cancer Causes Control"},{"key":"2835_CR19","first-page":"233","volume":"26","author":"SJ Klug","year":"2018","unstructured":"Klug SJ, Meerpohl J, Terhardt M et al (2018) Wissenschaftliche Begr\u00fcndung f\u00fcr die Empfehlung der HPV-Impfung f\u00fcr Jungen im Alter von 9 bis 14\u00a0Jahren. Epidemiol Bull 26:233\u2013254","journal-title":"Epidemiol Bull"},{"key":"2835_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00761-017-0231-9","volume":"23","author":"Y Garbe","year":"2017","unstructured":"Garbe Y, Klug SJ (2017) Aktueller Stand der HPV-Impfung in Deutschland. Onkologe 23:409\u2013414","journal-title":"Onkologe"},{"key":"2835_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","volume":"2","author":"SK Kjaer","year":"2009","unstructured":"Kjaer SK, Sigurdsson K, Iversen OE et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2:868\u2013878","journal-title":"Cancer. Prev. Res. (Phila)"},{"key":"2835_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","volume":"13","author":"M Lehtinen","year":"2012","unstructured":"Lehtinen M, Paavonen J, Wheeler CM et al (2012) Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4\u2011year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89\u201399","journal-title":"Lancet Oncol"},{"key":"2835_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00761-016-0092-7","volume":"22","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen N (2016) Epidemiologie, Pr\u00e4vention und Fr\u00fcherkennung des Zervixkarzinoms. Onkologe 22:725\u2013736","journal-title":"Onkologe"},{"key":"2835_CR24","first-page":"315","volume":"34","author":"Robert Koch-Institut","year":"2014","unstructured":"Robert Koch-Institut (2014) Humane Papillomaviren (HPV). Epidemiol Bull 34:315\u2013316","journal-title":"Epidemiol Bull"},{"key":"2835_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1186\/s12889-016-3663-z","volume":"16","author":"S Schulein","year":"2016","unstructured":"Schulein S, Taylor KJ, Konig J, Claus M, Blettner M, Klug SJ (2016) Factors influencing uptake of HPV vaccination among girls in Germany. BMC Public Health 16:995","journal-title":"BMC Public Health"},{"issue":"1","key":"2835_CR26","first-page":"1","volume":"2018","author":"Robert Koch-Institut","year":"2018","unstructured":"Robert Koch-Institut (2018) Aktuelles aus der KV-Impfsurveillance \u2013 Impfquoten ausgew\u00e4hlter Schutzimpfungen in Deutschland. Epidemiol Bull 2018(1):1\u201318","journal-title":"Epidemiol Bull"},{"key":"2835_CR27","volume-title":"S3-Leitlinie Pr\u00e4vention des Zervixkarzinoms","author":"Leitlinienprogramm Onkologie","year":"2017","unstructured":"Leitlinienprogramm Onkologie, AWMF, Deutsche Krebsgesellschaft e.\u202fV., Deutsche Krebshilfe e.\u202fV. (2017) S3-Leitlinie Pr\u00e4vention des Zervixkarzinoms. \n                    https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Zervixkarzinom_Praevention\/LL_Pr%C3%A4vention_des_Zervixkarzinoms_Langversion_1.0.pdf\n                    \n                  . Zugegriffen: 20. Apr. 2018"},{"key":"2835_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","volume":"11","author":"G Ronco","year":"2010","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F et al (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a\u00a0randomised controlled trial. Lancet Oncol 11:249\u2013257","journal-title":"Lancet Oncol"},{"key":"2835_CR29","volume-title":"Umsetzungsreifes Konzept f\u00fcr organisierte Fr\u00fcherkennung auf Geb\u00e4rmutterhalskrebs liegt vor","author":"Gemeinsamer Bundesausschuss (G-BA)","year":"2018","unstructured":"Gemeinsamer Bundesausschuss (G-BA) (2018) Umsetzungsreifes Konzept f\u00fcr organisierte Fr\u00fcherkennung auf Geb\u00e4rmutterhalskrebs liegt vor. \n                    https:\/\/www.g-ba.de\/institution\/presse\/pressemitteilungen\/742\/\n                    \n                  . Zugegriffen: 20. Apr. 2018"},{"key":"2835_CR30","first-page":"A132","volume":"3","author":"SJ Klug","year":"2003","unstructured":"Klug SJ, Blettner M (2003) Zervixkarzinom, HPV-Infektion und Screening \u2013 Stand der Dinge und Zukunftsperspektiven. Dtsch Arztebl 3:A132\u2013A136","journal-title":"Dtsch Arztebl"},{"key":"2835_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00103-013-1903-2","volume":"57","author":"U Seifert","year":"2014","unstructured":"Seifert U, Klug SJ (2014) Fr\u00fcherkennung des Zervixkarzinoms in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57:294\u2013301","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2835_CR32","first-page":"1","volume-title":"Evaluation of cervical cytology. Evidence report\/technology assessment (summary)","author":"DC McCrory","year":"1999","unstructured":"McCrory DC, Matchar DB, Bastian L et\u00a0al (1999) Evaluation of cervical cytology. Evidence report\/technology assessment (summary), S\u00a01\u20136"},{"key":"2835_CR33","first-page":"484","volume":"52","author":"K Marquardt","year":"2011","unstructured":"Marquardt K (2011) Zervixzytologie: Der repr\u00e4sentative Abstrich. Frauenarzt 52:484\u2013484","journal-title":"Frauenarzt"},{"key":"2835_CR34","doi-asserted-by":"publisher","first-page":"a1284","DOI":"10.1136\/bmj.a1284","volume":"337","author":"M Arbyn","year":"2008","unstructured":"Arbyn M, Kyrgiou M, Simoens C et al (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Br Med\u00a0J 337:a1284","journal-title":"Br Med J"},{"key":"2835_CR35","volume-title":"Zusammenstellung: Evidenzberichte und Zusatzmaterialien. F\u00fcr die Leitliniengruppe Pr\u00e4vention des Zervixkarzinoms","author":"M Arbyn","year":"2016","unstructured":"Arbyn M (2016) Zusammenstellung: Evidenzberichte und Zusatzmaterialien. F\u00fcr die Leitliniengruppe Pr\u00e4vention des Zervixkarzinoms. \n                    https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Zervixkarzinom_Praevention\/Zusammenstellung_Evidenzberichte_Arbyn_Zervixpraevention.pdf\n                    \n                  . Zugegriffen: 1. Febr. 2018"},{"key":"2835_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0140-6736(06)67961-0","volume":"367","author":"E Davey","year":"2006","unstructured":"Davey E, Barratt A, Irwig L et al (2006) Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a\u00a0systematic review. Lancet 367:122\u2013132","journal-title":"Lancet"},{"key":"2835_CR37","volume-title":"D\u00fcnnschichtpr\u00e4parationen und computergest\u00fctzte Untersuchungen von Zervixabstrichen Medizinische Effektivit\u00e4t, gesundheits-\u00f6konomische Evaluation und systematische Entscheidungsanalyse","author":"U Siebert","year":"2003","unstructured":"Siebert U, Muth C, Sroczynski G, Velasco-Garrido M, Gerhardus A, Gibis B (2003) D\u00fcnnschichtpr\u00e4parationen und computergest\u00fctzte Untersuchungen von Zervixabstrichen Medizinische Effektivit\u00e4t, gesundheits-\u00f6konomische Evaluation und systematische Entscheidungsanalyse"},{"key":"2835_CR38","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1002\/ijc.27955","volume":"132","author":"SJ Klug","year":"2013","unstructured":"Klug SJ, Neis KJ, Harlfinger W et al (2013) A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer 132:2849\u20132857","journal-title":"Int J Cancer"},{"key":"2835_CR39","volume-title":"BD Onclarity HPV Assay \u2013 P160037","author":"U.S. Food and Drug Administration","year":"2018","unstructured":"U.S. Food and Drug Administration (2018) BD Onclarity HPV Assay \u2013 P160037. \n                    https:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/DeviceApprovalsandClearances\/Recently-ApprovedDevices\/ucm598991.htm\n                    \n                  . Zugegriffen: 21. Juni 2018"},{"key":"2835_CR40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/jnci\/djj209","volume":"98","author":"G Ronco","year":"2006","unstructured":"Ronco G, Segnan N, Giorgi-Rossi P et al (2006) Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J\u00a0Natl Cancer Inst 98:765\u2013774","journal-title":"J Natl Cancer Inst"},{"key":"2835_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","volume":"13","author":"DC Rijkaart","year":"2012","unstructured":"Rijkaart DC, Berkhof J, Rozendaal L et al (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13:78\u201388","journal-title":"Lancet Oncol"},{"key":"2835_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstrom KM et al (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:524\u2013532","journal-title":"Lancet"},{"key":"2835_CR43","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ijc.24010","volume":"124","author":"CJ Meijer","year":"2009","unstructured":"Meijer CJ, Berkhof J, Castle PE et\u00a0al (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516\u2013520","journal-title":"Int J Cancer"},{"key":"2835_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/jnci\/djx225","volume":"110","author":"M Schiffman","year":"2018","unstructured":"Schiffman M, Kinney WK, Cheung LC et\u00a0al (2018) Relative performance of HPV and cytology components of cotesting in cervical screening. J\u00a0Natl Cancer Inst 110:501\u2013508","journal-title":"J Natl Cancer Inst"},{"key":"2835_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju153","author":"JC Gage","year":"2014","unstructured":"Gage JC, Schiffman M, Katki HA et\u00a0al (2014) Reassurance against future risk of precancer and cancer conferred by a\u00a0negative human papillomavirus test. J\u00a0Natl Cancer Inst. \n                    https:\/\/doi.org\/10.1093\/jnci\/dju153","journal-title":"J Natl Cancer Inst"},{"key":"2835_CR46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/fmb.11.87","volume":"6","author":"VV Sahasrabuddhe","year":"2011","unstructured":"Sahasrabuddhe VV, Luhn P, Wentzensen N (2011) Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol 6:1083\u20131098","journal-title":"Future Microbiol"},{"key":"2835_CR47","first-page":"1064","volume":"53","author":"F Girardi","year":"2012","unstructured":"Girardi F, Frey Tirri B, K\u00fcppers V, Menton M, Quaas J, Reich O (2012) Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011). Approbierte Darstellung und Erl\u00e4uterung f\u00fcr Deutschland, \u00d6sterreich und die deutschsprachige Schweiz. Frauenarzt 53:1064\u20131066","journal-title":"Frauenarzt"},{"key":"2835_CR48","volume-title":"European guidelines for quality assurance in cervical cancer screening","author":"M Arbyn","year":"2008","unstructured":"Arbyn M, Anttila A, Jordan J et\u00a0al (2008) European guidelines for quality assurance in cervical cancer screening. European Communities, Luxembourg"},{"key":"2835_CR49","series-title":"Bundesgesetzblatt 2013","first-page":"617","volume-title":"Gesetz zur Weiterentwicklung der Krebsfr\u00fcherkennung und zur Qualit\u00e4tssicherung durch klinische Krebsregister","author":"Deutscher Bundestag","year":"2013","unstructured":"Deutscher Bundestag (2013) Gesetz zur Weiterentwicklung der Krebsfr\u00fcherkennung und zur Qualit\u00e4tssicherung durch klinische Krebsregister. Bundesgesetzblatt 2013, S\u00a0617\u2013623"},{"key":"2835_CR50","volume-title":"Eckpunkte f\u00fcr zuk\u00fcnftiges Screening auf Geb\u00e4rmutterhalskrebs ge\u00e4ndert","author":"Gemeinsamer Bundesausschuss","year":"2016","unstructured":"Gemeinsamer Bundesausschuss (2016) Eckpunkte f\u00fcr zuk\u00fcnftiges Screening auf Geb\u00e4rmutterhalskrebs ge\u00e4ndert. \n                    https:\/\/www.g-ba.de\/downloads\/34-215-641\/38-2016-09-15_KFE-RL_Eckpunkte%20Zervix.pdf\n                    \n                  . Zugegriffen: 1. Febr. 2018"},{"key":"2835_CR51","volume-title":"Einladungsschreiben und Entscheidungshilfen zum Zervixkarzinom-Screening [invitation and decision aid for cervical cancer screening]: Abschlussbericht; Auftrag P15-02","author":"IQWiG","year":"2018","unstructured":"IQWiG (2018) Einladungsschreiben und Entscheidungshilfen zum Zervixkarzinom-Screening [invitation and decision aid for cervical cancer screening]: Abschlussbericht; Auftrag P15-02. \n                    https:\/\/www.iqwig.de\/en\/projects-results\/projects\/health-information\/p15-02-invitation-and-decision-aid-for-cervical-cancer-screening.6621.html\n                    \n                  . Zugegriffen: 20. Apr. 2018"},{"key":"2835_CR52","volume-title":"Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine Beauftragung des IQTIG: Entwicklung eines Konzepts f\u00fcr die Programmbeurteilung des organisierten Zervixkarzinomscreenings","author":"Gemeinsamer Bundesausschuss","year":"2017","unstructured":"Gemeinsamer Bundesausschuss (2017) Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine Beauftragung des IQTIG: Entwicklung eines Konzepts f\u00fcr die Programmbeurteilung des organisierten Zervixkarzinomscreenings. \n                    https:\/\/www.g-ba.de\/downloads\/39-261-2851\/2017-01-19_IQTIG-Beauftragung_Programmbeurteilung-Zervixkarzinomscreening.pdf\n                    \n                  . Zugegriffen: 20. Apr. 2018"},{"key":"2835_CR53","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1309\/RNF3C01JKADQCLKP","volume":"127","author":"MH Stoler","year":"2007","unstructured":"Stoler MH, Castle PE, Solomon D, Schiffman M (2007) The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 127:335\u2013337","journal-title":"Am J Clin Pathol"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-018-2835-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-018-2835-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-018-2835-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:15:00Z","timestamp":1572912900000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-018-2835-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2835"],"URL":"https:\/\/doi.org\/10.1007\/s00103-018-2835-7","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"assertion":[{"value":"5 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Bujan Rivera und S.J.\u00a0Klug geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}